Most Read Articles
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.

Gadopiclenol does not prolong QTc interval in healthy individuals

21 Nov 2020

A new gadolinium-based contrast agent, gadopiclenol, at clinical and supraclinical doses does not result in prolonged QT interval and has an acceptable safety profile among healthy volunteers, a recent study has found.

“The positive slope of the QTc prolongation vs concentration relationship suggests that hyperosmolarity could be associated with QTc prolongation,” the investigators said. “However, the amplitude of this effects is unlikely to be associated with proarrhythmia.”

This single-centre, randomized, double-blind, placebo- and positive-controlled, four-way crossover study included 48 healthy male and female individuals who received single intravenous (IV) administration of gadopiclenol at a clinical dose of 0.1 mmol kg-1 (standard for current gadolinium-based contrast agents), a supraclinical dose of 0.3 mmol kg-1, placebo, and a single oral dose of moxifloxacin 400 mg.

The biggest time‐matched, placebo‐corrected, mean change from‐baseline in QTcF (ΔΔQTcF) was seen 3 hours after administration of 0.1 mmol kg−1 gadopiclenol (2.39 ms, 90 percent confidence interval [CI], 0.35–4.43) and 5 minutes after administration of 0.3 mmol kg−1 (4.81 ms, 90 percent CI, 2.84–6.78).

The upper limit of the 90 percent CI was under the threshold of 10 ms, which showed no substantial effect of gadopiclenol on QTc interval. The lower limit of the 90 percent CI of ΔΔQTcF from 1.5–4 hours postdose moxifloxacin exceeded 5 ms, indicating assay sensitivity.

A positive slope was observed, but the concentration–response analysis estimated that the values of ΔΔQTcF at the maximal concentration of gadopiclenol at 0.1 and 0.3 mmol kg-1 were 0.41 and 2.23 ms, respectively, with the upper limit of the 90 percent CI not exceeding 10 ms.

There were no serious or adverse events (AEs) or treatment discontinuations due to AEs reported, according to the investigators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.